A Proposed Content-Uniformity Test for Large Sample Sizes - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A Proposed Content-Uniformity Test for Large Sample Sizes
The authors describe a modified version of the Large-N test used to determine content uniformity.

Pharmaceutical Technology
pp. 72-79


The authors wish to thank Fasheng Li, associate director of statistics–Groton at Pfizer (New York) for creating the plots used in the paper. Thank you to Tom Garcia, a research fellow for global regulatory CMC–Groton at Pfizer and Ambarish Singh, associate director of global regulatory sciences–CMC at Bristol-Myers Squibb (New York) for reviewing the paper.

James Bergum* is an associate director of nonclinical biostatistics at Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, NJ 08903, tel. 732.227.5981, fax 732.227.3005,
. Kim Erland Vukovinsky is a director of nonclinical statistics at Pfizer.

*To whom all correspondence should be addressed.

Submitted: Mar. 15, 2010. Accepted: Apr. 12, 2010.


1. USP 33–NF 28 Reissue, General Chapter <905>, "Uniformity of Dosage Units," (US Pharmacopeial Convention, Rockville, MD, Oct. 2010, pp. R–86).

2. D. Sandell, et al., Drug Info. J., 40, 337–344 (2006).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here